#Tandem autologous stem cell transplant series

All autografted patients were included in the study, regardless of availability of complete MED-A or MED-B data. Consent appropriate to the time of transplant was obtained from all patients for the anonymized reporting of their data and the use of the data for retrospective studies. All patients were reported to the EBMT registry using MED-A (limited data set) or MED-B (more extensive data set) forms. Here, we report an European Group for Blood and Marrow Transplantation (EBMT) registry study comparing presenting features and outcomes of 272 patients with primary PCL and 20844 patients with multiple myeloma undergoing autologous transplantation between 19.Ī retrospective study was carried out of 20844 patients with common type multiple myeloma (58% IgG, 21% IgA and 19% light chain only types) and 272 patients with primary PCL who underwent first autologous transplantation between 19. 2 Prolonged survival has also been reported for individual cases after intensive chemotherapy and hematopoietic stem cell support. 1, 2 Polychemotherapy may offer significantly enhanced survival, with one study reporting a median survival of 18 months among patients treated in this way compared to 3 months among patients given alkylating agent therapy.

#Tandem autologous stem cell transplant series

2, 4, 5 Treatment of PCL with alkylating agent-based therapy is ineffective with no responding patients in a series of ten patients treated with melphalan and prednisolone 1 and a median survival of 2–3 months. 4 Patients are reported to present often with advanced stage, extramedullary involvement, raised lactate dehydrogenase and thrombocytopenia 1 while cytogenetic abnormalities, including hypodiploidy, pseudo-diploidy, complex abnormalities and monosomy 13, have been described more frequently than in advanced myeloma. 1 The disorder progresses rapidly with frequent early deaths for example, 11 of a series of 40 patients with primary PCL died in the first month after diagnosis. Considered to represent advanced disease with a poor prognosis, the median survival of patients with PCL is reported to be 8 to 12 months, 1, 2 which is significantly shorter than that for patients with multiple myeloma, even when the comparison is adjusted to compare only cases of multiple myeloma with a high tumor mass. 3 as an absolute plasma cell count of more than 2.0×10 9/L or a relative proportion of greater than 20% of the peripheral blood leukocyte count. Diagnostic criteria were defined by Kyle et al. Primary plasma cell leukemia (PCL) is a rare disorder, representing less than 5% of malignant plasma cell diseases, 1, 2 and characterized by plasma cells circulating in the peripheral blood.